Question 1

Has Alejandra de Alba Campomanes, MD received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $142,278 in general payments to Alejandra de Alba Campomanes, MD across 31 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Alejandra de Alba Campomanes, MD did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Alejandra de Alba Campomanes, MD come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Regeneron	27	$140,338
Novartis	1	$1,815
AbbVie	1	$95
Carl Zeiss Meditec AG	1	$19
Travere Therapeutics, Inc.	1	$11

Alejandra de Alba Campomanes, MD

Payments from drug & device makers

Who reported the general payments

How this compares

Medicare billing

Other ophthalmology in San Francisco